Renovorx announces third quarter 2021 financial results

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended september 30, 2021. “the third quarter of 2021 marked an important juncture in the growth of our company as we completed our ipo in late august and our seventh u.s. patent was issued for our renovotamp™ (renovorx trans-arterial micro-perfusion) therapy platform. our team remains patient
RNXT Ratings Summary
RNXT Quant Ranking